Background/Aims: The single nucleotide polymorphism (SNP) rs1893217 within the gene locus encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) results in a dysfunctional PTPN2 protein is associated with Crohn's disease (CD) and exists in perfect linkage disequilibrium with the CD- and ulcerative colitis (UC)-associated PTPN2 SNP rs2542151. We investigated associations of PTPN2 SNP rs1893217 and clinical characteristics of inflammatory bowel disease (IBD) patients. Methods: One thousand seventy three patients with CD and 734 patients with UC from the Swiss IBD Cohort Study (SIBDCS) were included. Epidemiologic, disease and treatment characteristics were analysed for an association with the presence of one of the rs1893217 genotypes ‘homozygous wild-type' (TT), ‘heterozygous' (CT) and ‘homozygous variant' (CC). Results: About 2.88% of IBD patients were identified with CC, 26.8% with CT and 70.4% with TT genotype. The CC-genotype was associated with the existence of gallstones in CD and pancolitis in UC patients. The presence of the C-allele (i.e. either CC or CT genotype) was associated with the onset of uveitis, but protected from aphthous oral ulcers in CD patients. UC patients carrying a C-allele were diagnosed at an older age but required intestinal surgery more often. The presence of the C-allele was associated with a successful treatment with anti-TNF antibodies in both CD and UC patients. Conclusion: IBD patients carrying the C-allele of PTPN2 SNP rs1893217 are at greater risk for developing a severe disease course but are more likely to respond to treatment with anti-TNF antibodies. These findings demonstrate a clinical relevance of this PTPN2 risk variant in IBD patients.

Journal Section:
Original Paper
Keywords:
Pancolitis, Inflammatory bowel disease, Protein tyrosine phosphatase non-receptor type 2, Genetic polymorphisms, Anti-TNF antibodies
1.
Jostins L, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
2.
Liu JZ, et al: Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015;47:979-986.
3.
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
4.
Scharl M, et al: Crohn's disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy. Inflamm Bowel Dis 2012;18:900-912.
5.
Franke A, et al: Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008;40:713-715.
6.
Todd JA, et al: Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-864.
7.
Scharl M, et al: Protein tyrosine phosphatase nonreceptor type 2 regulates autophagosome formation in human intestinal cells. Inflamm Bowel Dis 2012;18:1287-1302.
8.
Scharl M, et al: Protection of epithelial barrier function by the Crohn's disease associated gene protein tyrosine phosphatase N2. Gastroenterology 2009;137:2030-2040.e5.
9.
Scharl M, et al: Protein tyrosine phosphatase N2 regulates TNFα-induced signalling and cytokine secretion in human intestinal epithelial cells. Gut 2011;60:189-197.
10.
Scharl M, Hruz P, McCole DF: Protein tyrosine phosphatase non-receptor type 2 regulates IFN-γ-induced cytokine signaling in THP-1 monocytes. Inflamm Bowel Dis 2010;16:2055-2064.
11.
Heinonen KM, et al: T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease. Blood 2004;103:3457-3464.
12.
You-Ten KE, et al: Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997;186:683-693.
13.
Wiede F, et al: T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J Clin Invest 2011;121:4758-4774.
14.
Wiede F, La Gruta NL, Tiganis T: PTPN2 attenuates T-cell lymphopenia-induced proliferation. Nat Commun 2014;5:3073.
15.
Spalinger MR, et al: PTPN2 controls differentiation of CD4+ T cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunol 2015;8:918-929.
16.
Pittet V, et al: Cohort profile: the Swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol 2009;38:922-931.
17.
Silverberg MS, et al: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A.
18.
Veitia RA, Bottani S, Birchler JA: Gene dosage effects: nonlinearities, genetic interactions, and dosage compensation. Trends Genet 2013;29:385-393.
19.
Chou CM, et al: Biochemical basis for dominant inheritance, variable penetrance, and maternal effects in RBP4 congenital eye disease. Cell 2015;161:634-646.
20.
Vavricka SR, et al: Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011;106:110-119.
21.
Barrie A, Regueiro M: Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1424-1429.
22.
Greenstein AJ, Janowitz HD, Sachar DB: The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-412.
23.
Dorofeyev AE, Vasilenko IV, Rassokhina OA: Joint extraintestinal manifestations in ulcerative colitis. Dig Dis 2009;27:502-510.
24.
Monsén U, et al: Extracolonic diagnoses in ulcerative colitis: an epidemiological study. Am J Gastroenterol 1990;85:711-716.
25.
Lankarani KB, Sivandzadeh GR, Hassanpour S: Oral manifestation in inflammatory bowel disease: a review. World J Gastroenterol 2013;19:8571-8579.
26.
McCullough MJ, Abdel-Hafeth S, Scully C: Recurrent aphthous stomatitis revisited; clinical features, associations, and new association with infant feeding practices? J Oral Pathol Med 2007;36:615-620.
27.
Hutchinson R, et al: Pathogenesis of gall stones in Crohn's disease: an alternative explanation. Gut 1994;35:94-97.
28.
Jahnel J, et al: Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos 2014;42:1423-1431.
29.
van Vliet C, et al: Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat Immunol 2005;6:253-260.
30.
Hassan SW, et al: Increased susceptibility to dextran sulfate sodium induced colitis in the T cell protein tyrosine phosphatase heterozygous mouse. PLoS One 2010;5:e8868.
31.
Solus JF, et al: Genetics of serum concentration of IL-6 and TNFα in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol 2015;34:1375-1382.
32.
MacDonald TT, et al: Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-305.
33.
Reinecker HC, et al: Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-181.
34.
Van Assche G, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010;4:63-101.
35.
Dignass A, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
36.
Rutgeerts P, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
37.
Cohen RD, Tsang JF, Hanauer SB: Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-3477.
38.
Ljung T, et al: Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-853.
39.
Oussalah A, et al: A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010;105:2617-2625.
40.
Gavalas E, et al: Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients. Hepatogastroenterology 2007;54:1074-1079.
41.
Bank S, et al: Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases. Dan Med J 2015;62:pii:A4994..
42.
Nguyen DL, Nguyen ET, Bechtold ML: pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. South Med J 2015;108:139-143.
43.
Arijs I, et al: Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009;58:1612-1619.
44.
Arijs I, et al: Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010;16:2090-2098.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.